Skip to main content
Fig. 2 | Fluids and Barriers of the CNS

Fig. 2

From: Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab

Fig. 2

GBM in 44 y/o male: GBCA enhancement on T1-weighted pre- (a, ROIpre) and post-BEV (d, ROIpost). rCBV maps derived from ferumoxytol DSC pre- (b) and post-BEV (e) overlaid on the enhancing volume. An overlay of the post-BEV rCBV map on ROIpre can be found in c. “Hot spot” regions are indicated by white arrows; note the marked decrease in rCBV between b and c

Back to article page